Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery

Michael A. Gorin, Obi Ekwenna, Mark S Soloway, Gaetano Ciancio

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.

Original languageEnglish (US)
Pages (from-to)e11
JournalUrology
Volume79
Issue number2
DOIs
StatePublished - Feb 1 2012

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery'. Together they form a unique fingerprint.

  • Cite this